Debjani Pal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Debjani Pal has a total of 113 co-authors. Here are the top co-authors by number of shared publications:
- Alexander M. Taylor
Relay Therapeutics, 60 Hampshire Street, Cambridge, Massachusetts 02139, United States
78 shared publications - Alison M. Schram
Memorial Sloan Kettering Cancer Center, New York, NY
78 shared publications - B. Barry. Toure
Relay Therapeutics, Cambridge, MA 02139
78 shared publications - Beni B. Wolf
Relay Therapeutics, Inc., Cambridge, Massachusetts
78 shared publications - Brandi M. Hudson
Relay Therapeutics, Cambridge, MA 02139
78 shared publications - Cori Ann Sherwin
Relay Therapeutics, Inc., Cambridge, Massachusetts
78 shared publications
Latest Publications
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
Supplementary Figure 2. Treatment with RLY-4008 is well-tolerated and leads to dose-dependent inhibition of FGFR2 and tumor regression in multiple FGFR2-altered tumor models.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
Supplementary Figure 2. Treatment with RLY-4008 is well-tolerated and leads to dose-dependent inhibition of FGFR2 and tumor regression in multiple FGFR2-altered tumor models.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
Potency (kinact/KI) of RLY-4008 against FGFR1 and FGFR2
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
Potency (kinact/KI) of RLY-4008 against FGFR1 and FGFR2
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Video S1 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
In this schematic movie, apo FGFR1 (left panel) demonstrates rapid P-loop dynamics, while apo FGFR2 (right panel) displays less P-loop motion.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video S1 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
In this schematic movie, apo FGFR1 (left panel) demonstrates rapid P-loop dynamics, while apo FGFR2 (right panel) displays less P-loop motion.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
Biochemical inhibition of FGFR by RLY-4008 and pan-FGFRi
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
Biochemical inhibition of FGFR by RLY-4008 and pan-FGFRi
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary References from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
Three references cited in supplementary data
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary References from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
Three references cited in supplementary data
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Video S1 Legend from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
Supplementary video legend describing schematic video of P-loop dynamics
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video S1 Legend from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
Supplementary video legend describing schematic video of P-loop dynamics
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
Supplementary Figure 1. RLY-4008 is an irreversible inhibitor of FGFR2.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
Supplementary Figure 1. RLY-4008 is an irreversible inhibitor of FGFR2.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
Fold change in potency against FGFR2 acquired resistance mutations
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
Fold change in potency against FGFR2 acquired resistance mutations
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
In vivo exposures of pan-FGFRi in mouse studies
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
In vivo exposures of pan-FGFRi in mouse studies
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
Antiproliferative effect of RLY-4008 and pan-FGFRi in human tumor cell lines
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
Antiproliferative effect of RLY-4008 and pan-FGFRi in human tumor cell lines